INTRODUCTION
============

Malignant peripheral nerve sheath tumors (MPNSTs) are rare and highly aggressive neoplasms, representing only 5% of soft tissue sarcomas ([@b1-cln_67p963],[@b2-cln_67p963]). Approximately half of MPNST cases occur in association with neurofibromatosis type 1 (NF1) ([@b3-cln_67p963]). MPNSTs may appear *de novo* or develop from the malignant transformation of a benign neural neoplasm, generally a plexiform neurofibroma ([@b1-cln_67p963]). Solitary (unassociated with NF1) and localized (or discrete; multiple in NF1) neurofibromas do not have malignant transformation potential ([@b1-cln_67p963],[@b3-cln_67p963]). *NF1* loss of heterozygosity (LOH) has been demonstrated in NF1-associated and sporadic MPNSTs. Although *NF1* LOH is believed to be sufficient for neurofibroma development, MPNST pathogenesis has been suggested to be a multistage process that includes other molecular alterations ([@b4-cln_67p963],[@b5-cln_67p963]). *TP53* mutations have been found in a subgroup of MPNSTs, indicating that a p53-mediated pathway is involved in their development ([@b5-cln_67p963],[@b6-cln_67p963]).

Some clinicopathological features (e.g., the presence of NF1, high histological grade, necrosis, and rhabdomyoblastic differentiation) have been indicated to be important factors for lower survival in MPNST cases in some studies but not in others ([@b2-cln_67p963],[@b7-cln_67p963])--([@b10-cln_67p963]). The clinical significance of p53 expression in MPNSTs is also a controversial issue. We aimed to study p53 expression in MPNSTs and investigate its impact, as well as the impacts of the clinicopathological features of MPNSTs, on the survival rates. We also compared p53 expression in MPNSTs with their clinicopathological features and with p53 expression in neurofibromas.

MATERIALS AND METHODS
=====================

The Ethical Committee of the National Institute of Cancer (INCA), RJ, Brazil, approved this study.

Case Selection
--------------

MPNSTs diagnosed from 1996-2005 were obtained from the pathology files of INCA. The following inclusion criteria were used: available medical records and preserved paraffin blocks from the resected primary tumor with a sufficient quantity of material (in patients submitted to radiotherapy and/or chemotherapy prior to primary tumor resection, the biopsy material was used if it had the same histological grade as the resected material). Tumors with one of the following features were included: arose within a peripheral nerve; arose during the transition from a benign neural tumor; developed in a NF1 patient and exhibited the same histological features of most MPNSTs originating from a nerve; and developed in a non-NF1 patient, exhibited the same histological features as most MPNSTs and expressed S-100 (Dako Corp., Carpinteria, CA, USA, 1:4,000) and/or CD57 (clone TB01; Dako, 1:50). All samples were immunoreactive for anti-vimentin (clone V9; Dako, 1:800) and negative for anti-cytokeratin (clone AE1/AE3; Dako, 1:400), anti-melanosome, (clone HMB-45, 1:200), anti-actin (smooth muscle; clone 1A4; Dako, 1:250), anti-actin/muscle (clone HHF35; Dako, 1:1,000), and anti-desmin (clone D33; Dako, 1:100) antibodies, except the malignant triton tumors, which exhibited anti-actin/muscle and desmin immunopositive areas. The immunohistochemistry (IHC) was performed after reviewing the H&E sections.

Plexiform neurofibromas diagnosed from 1996-2005 were obtained from the pathology files of INCA. The following inclusion criteria were used: available medical records, preserved paraffin blocks with sufficient quantity of material and presence of heterogeneous and diffuse expression of S-100 protein. The other selected neurofibromas had been used in two previous studies ([@b11-cln_67p963],[@b12-cln_67p963]).

The diagnoses of all the MPNSTs and neurofibromas were confirmed by two pathologists.

Histological Analysis of Malignant Peripheral Nerve Sheath Tumors
-----------------------------------------------------------------

[Tables 1](#t1-cln_67p963){ref-type="table"} and [2](#t2-cln_67p963){ref-type="table"} show the clinical and pathological features, respectively, of the MPNSTs analyzed in this research. The tumors were classified as low- or high-grade according to the Armed Forces Institutes of Pathology criteria ([@b1-cln_67p963]).

The epithelioid MPNSTs included in this study were composed predominantly of epithelioid cells and exhibited spindle cells identical to those of conventional MPNSTs. The malignant triton tumors had areas of cells with rhabdomyoblast morphology, which expressed desmin and/or actin/muscle.

Construction of Tissue Microarray Paraffin Blocks
-------------------------------------------------

Two tissue microarray (TMA) paraffin blocks containing samples from all tumors were constructed. Five morphologically representative regions of each tumor were marked with a colored pen on the glass slides of H&E sections. Areas of necrosis and severe inflammatory infiltration were avoided. From each corresponding original paraffin block, five tissue cores (1.1 mm in diameter) were sampled from the marked areas in the donor block and mounted onto a recipient paraffin block, using the alternative method for the manual construction of TMAs ([@b13-cln_67p963]).

Immunohistochemistry
--------------------

Sections of 3 µm in thickness were cut and collected on silane-coated slides. After dewaxing, the p53 protein expression was assessed by IHC (anti-p53 antibody; clone DO-7; Dako Corporation, 1:100) using a protocol described elsewhere ([@b14-cln_67p963]). A metastatic carcinoma was used as the positive control, and the omission of the primary antibody was used to establish the negative control.

The quantification of the p53 staining was performed with computerized digital image analysis (Image-Pro Plus software v4.5; Media Cybernetics), as previously described ([@b14-cln_67p963]). The quantification was expressed as the positivity index (PI), which was defined as the p53-positive area divided by the tissue area. The tumors were classified as having low or high PIs (cut-off value = 0.0020). The intensity of the p53 expression (weak, moderate, or intense) was also evaluated.

Statistical Analysis
--------------------

Clinicopathological and immunohistochemical variables were compared using the chi-squared, Fisher\'s exact, Student\'s t-, and Mann-Whitney U tests. The Kaplan-Meier method was used to evaluate the survival curves. The statistical significance of the clinicopathological variables was determined with the log-rank test. Multivariate analysis was performed using the Cox regression model. SPSS software v.11 was used for the statistical analyses. Differences were considered significant if *p*\<0.05.

RESULTS
=======

Twenty-eight MPNSTs and thirty-eight neurofibromas were included in this study.

[Figures 1A](#f1-cln_67p963){ref-type="fig"}--[1C](#f1-cln_67p963){ref-type="fig"} show some examples of MPNST included in the study (malignant triton tumor and MPNST with chondrosarcoma differentiation).

The overall and disease-free five-year survival rates of the MPNST patients were 46 and 39%, respectively. The data regarding the p53 expression in the MPNSTs and neurofibromas are described in [Tables 2](#t2-cln_67p963){ref-type="table"} and [3](#t3-cln_67p963){ref-type="table"}. p53 expression was more common in the MPNSTs than in the neurofibromas (χ^2^ *p*\<0.001). The only p53-positive neurofibroma (plexiform neurofibroma) presented weak nuclear immunoreactivity. In the MPNSTs, the nuclear p53 expression varied from weak to intense.

[Figures 1D](#f1-cln_67p963){ref-type="fig"}--[1F](#f1-cln_67p963){ref-type="fig"} show the expression of p53 in the plexiform neurofibroma and in two MPNSTs.

The p53 expression was not correlated with any of the following clinicopathological features of MPNSTs (Fisher\'s exact test): NF1 (*p = *0.433), local recurrence (*p = *0.642), metastasis (*p = *0.125), high grade (*p = *0.364), high mitotic index (*p = *0.278), and necrosis (*p = *0.249).

In the p53-positive MPNSTs, there was no correlation of high PI with the clinicopathological variables (Mann-Whitney test): NF1 (*p = *0.179), local recurrence (*p = *0.643), metastasis (*p = *0.353), high grade (*p = *0.208), high mitotic index (*p = *0.156), and necrosis (*p = *0.387).

The epithelioid variant (*p = *0.036) was the only significant variable in the log-rank analysis of disease-free survival ([Table 4](#t4-cln_67p963){ref-type="table"}). The Cox regression analysis showed that necrosis (*p = *0.024) was an independent prognostic factor for lower overall survival (*p = *0.007) ([Table 5](#t5-cln_67p963){ref-type="table"}).

DISCUSSION
==========

The five-year overall survival rate of patients with MPNSTs has been reported to range from 23% to approximately 50% ([@b2-cln_67p963],[@b15-cln_67p963])--([@b17-cln_67p963]), similar to the rate of 46% found in this study. In our study, seven patients censored in the overall survival calculation had recurrence or metastasis, and three patients were lost to follow-up when the disease became terminal. Their deaths most likely went unobserved; therefore, their overall survival time may have been overestimated. This issue is usually a bias inherent in retrospective studies that intend to measure overall survival.

Although some authors have demonstrated the correlation of various clinicopathological parameters with the biological behavior of the MPNSTs, there is no consensus with regard to the importance of these factors in the prognosis of MPNST ([@b2-cln_67p963],[@b7-cln_67p963])--([@b10-cln_67p963]). In our study, the presence of necrosis was an independent predictor of mortality.

In the present work, only one (2.6%) neurofibroma (plexiform neurofibroma) expressed p53. Other studies have also demonstrated that p53 expression is rare or absent in neurofibromas ([@b18-cln_67p963])--([@b21-cln_67p963]). In contrast, the majority (64.3%) of MPNSTs expressed p53. Our results are similar to those of previous studies that used the same anti-p53 antibody clone, and the results of these studies showed that p53 expression in the MPNSTs varies from 42 to 100% (6,9,16,18--20,22). To our knowledge, there are only two previous studies that used TMA technology to investigate p53 expression in MPNSTs ([@b16-cln_67p963],[@b22-cln_67p963]).

In some studies ([@b9-cln_67p963],[@b20-cln_67p963],[@b21-cln_67p963]), an association between p53 expression and histological grade was observed, which differs from our research and that of others ([@b18-cln_67p963],[@b19-cln_67p963]). One explanation for these divergent results could be the different criteria adopted for histological gradation. Although the United States National Institutes of Cancer and *Fédération Nationale des Centres de Lutte Contre le Cancer* (FNCLCC) grading systems are the most commonly used systems for sarcomas, the histological grading systems for sarcomas have no prognostic value for some histological subtypes, including MPNSTs ([@b23-cln_67p963]). Therefore, we preferred to use a simple system in which MPNSTs are classified into two grades: low and high ([@b1-cln_67p963]).

We could not observe any influence of p53 expression on survival rates, similar to the results of a previous study ([@b24-cln_67p963]). In contrast, other researchers showed that p53 expression was an important predictive factor for lower survival rate ([@b16-cln_67p963],[@b19-cln_67p963]). In some studies ([@b16-cln_67p963],[@b22-cln_67p963]), p53 expression was more common in neurofibromas associated with NF1 than in those not associated with NF1, but other studies ([@b20-cln_67p963]) did not observe this association, similar to our results. There are a few possible explanations for these divergent results. First, some authors considered all cases that had any immunopositive cells as being positive, whereas others established cut-off points, varying from 3 to 10% of positive cells ([@b9-cln_67p963],[@b20-cln_67p963])--([@b22-cln_67p963]). Another important factor is that all previous studies used conventional pathologist-based manual scoring to quantify the p53 staining, which increases the inter-observer and intra-observer variabilities. Our study was the first to use computerized image analysis to calculate the p53 expression. Moreover, technical considerations, such as the storage time of the tissue sections on glass slides, can influence p53 immunoreactivity.

Necrosis was an important prognostic factor for lower overall survival, and the epithelioid variant was an important prognostic factor for shorter disease-free survival. p53 expression was not associated with any clinicopathological features and did not have an impact on the survival rates of the MPNST patients. p53 expression was rare in the neurofibromas and common in the MPNSTs, showing that the p53 pathway most likely plays an important role in the tumorigenesis of MPNSTs.

No potential conflict of interest was reported.

![Malignant triton tumor: case 4 (A and B). **A.** Area of differentiation in the rhabdomyosarcoma (arrows); H&E, 40x. **B.** Cells immunopositive for desmin; immunohistochemistry (diaminobenzidine), 40x. **C.** Malignant peripheral nerve sheath tumor with heterologous differentiation in a chondrosarcoma: case 13; H&E, 20x. **D.** p53-immunopositive plexiform neurofibroma (arrow); immunohistochemistry (diaminobenzidine), 40x. **E.** Malignant peripheral nerve sheath tumor immunoreactive for p53: case 24; immunohistochemistry (diaminobenzidine), 40x. **F.** Malignant peripheral nerve sheath tumor immunoreactive for p53: case 4; immunohistochemistry (diaminobenzidine), 40x. OBS: positive cells in brown.](cln-67-08-963-g001){#f1-cln_67p963}

###### 

Clinical data of the patients with malignant peripheral nerve sheath tumors.

  Patient   Age at diagnosis   Gender   Race   NF1   Site               Free surgical margins   Treatment         Local recurrence   Metastasis   Site of metastasis   Death   Overall survival (months)   Disease-free survival (months)
  --------- ------------------ -------- ------ ----- ------------------ ----------------------- ----------------- ------------------ ------------ -------------------- ------- --------------------------- --------------------------------
  1         27                 F        ---    Yes   Lumbar             No                      Resection         Yes                No                                No      21.60                       18.23
  2         44                 F        W      No    Left elbow         No                      Resection + Rxt   No                 No                                No      13.60                       13.60
  3         29                 F        ---    Yes   Right flank        No                      Resection + Rxt   No                 No                                Yes     12.47                       12.47
  4         23                 F        B      Yes   Pelvis             No                      Resection         No                 No                                Yes     4.87                        4.87
  5         28                 F        W      Yes   Right flank        Yes                     Resection         No                 No                                No      76.13                       76.13
  6         32                 F        W      No    Left lower limb    Yes                     Resection         No                 Yes          Lung                 No      12.10                       .00\*
  7         34                 F        W      No    Right lower limb   Yes                     Resection         No                 No                                No      44.77                       44.77
  8         40                 F        W      No    Breast             No                      Resection + Rxt   No                 No                                No      96.90                       96.90
  9         20                 F        ---    Yes   Lumbar             ---                     Rxt               No                 No                                Yes     1.83                        1.83
  10        53                 F        B      Yes   Left shoulder      Yes                     Resection         No                 No                                Yes     10.87                       10.87
  11        21                 F        W      Yes   Left lower limb    Yes                     Resection         No                 No                                No      67.50                       67.50
  12        23                 M        W      Yes   Left lower limb    ---                     Ct                No                 Yes          Lung                 Yes     2.73                        .00\*
  13        42                 F        W      No    Pelvis             No                      Resection + Rxt   No                 Yes          Liver and pancreas   Yes     11.30                       9.60
  14        68                 M        W      No    Right upper limb   ---                     Resection + Rxt   Yes                No                                No      9.50                        7.00
  15        19                 M        W      No    Right upper limb   ---                     Rxt               No                 Yes          Lung                 No      16.10                       .00\*
  16        23                 F        W      Yes   Sacrum and spine   ---                     Rxt               No                 Yes          Lung                 Yes     7.73                        7.67
  17        34                 F        B      Yes   Abdomen            No                      Resection         Yes                No                                No      10.10                       5.43
  18        60                 F        B      Yes   Right lower limb   Yes                     Resection         No                 Yes          Lung                 No      40.80                       22.83
  19        40                 F        B      No    Thorax             Yes                     Resection + Rxt   No                 No                                No      61.10                       61.10
  20        78                 F        W      No    Face sinus         No                      Resection + Rxt   Yes                No                                Yes     77.90                       50.20
  21        24                 M        W      Yes   Right upper limb   ---                     Biopsy + Ct       No                 Yes          Lung                 Yes     12.80                       6.60
  22        45                 M        B      Yes   Abdomen            ----                    Resection         Yes                Yes          Lung                 Yes     14.70                       13.07
  23        63                 M        B      Yes   Supraclavicular    Yes                     Resection         No                 No                                Yes     60.30                       60.30
  24        85                 M        W      No    Head (temporal)    Yes                     Resection         No                 No                                Yes     20.20                       20.20
  25        72                 F        W      No    Left lower limb    Yes                     Resection + Rxt   No                 Yes          Lung                 Yes     42.00                       39.93
  26        80                 F        W      No    Right foot         Yes                     Resection         Yes                No                                Yes     13.40                       8.10
  27        30                 F        B      No    Thorax             Yes                     Resection + Rxt   No                 Yes          Bone                 No      35.70                       4.67
  28        41                 M        B      Yes   Right lower limb   ---                     Rxt               No                 Yes          Cervical region      Yes     7.20                        6.97

###### 

Pathological data of the malignant peripheral nerve sheath tumors.

  Case number   Size(cm)   Grade   Presence of heterologous differentiation   Necrosis   Mitotic index(mitotic figures in10 high-power fields)\*   p53 PI values
  ------------- ---------- ------- ------------------------------------------ ---------- --------------------------------------------------------- ---------------
  1             4.6        high    no                                         no         7.0 (s.d. = 2.0)                                          0.00070
  2             17.0       high    rhabdomyosarcomatous areas                 yes        9.3 (s.d. = 1.5)                                          0.00
  3             15.0       high    no                                         yes        5.3 (s.d. = 1.2)                                          0.00020
  4             21.0       high    rhabdomyosarcomatous areas                 yes        17.0 (s.d. = 2.0)                                         0.01597
  5             7.0        low     chondrosarcomatous areas                   no         3.7 (s.d. = 1.5)                                          0.00010
  6             21.0       high    no                                         yes        7.0 (s.d. = 3.5)                                          0.00
  7             10.0       high    no                                         no         9.0 (s.d. = 2.0)                                          0.00
  8             16.0       low     no                                         no         0.3 (s.d. = 0.6)                                          0.00090
  9             ---        high    no                                         no         18.0 (s.d. = 4.0)                                         0.00160
  10            28.0       high    no                                         yes        19.0 (s.d. = 1.0)                                         0.00050
  11            17.0       high    no                                         yes        13.0 (s.d. = 2.6)                                         0.00280
  12            ---        high    no                                         yes        10.7 (s.d. = 1.5)                                         0.00040
  13            13.0       high    chondrosarcomatous areas                   yes        10.3 (s.d. = 5.7)                                         0.00
  14            ---        high    no                                         no         10.3 (s.d. = 4.0)                                         0.00
  15            ---        low     epithelioid                                no         3.0 (s.d. = 0.0)                                          0.00
  16            ---        high    no                                         yes        7.0 (s.d. = 2.6)                                          0.00170
  17            13.0       high    epithelioid                                yes        7.3 (s.d. = 1.2)                                          0.00
  18            12.0       high    chondrosarcomatous area                    no         6.0 (s.d. = 2.0)                                          0.00
  19            6.0        low     no                                         no         2.3 (s.d. = 1.5)                                          0.00200
  20            ---        low     no                                         no         3.0 (s.d. = 1.0)                                          0.00030
  21            ---        high    no                                         yes        7.0 (s.d. = 2.0)                                          0.00
  22            23.0       high    no                                         yes        13.3 (s.d. = 3.2)                                         0.00060
  23            5.0        high    chondroma area                             no         7.0 (s.d. = 2.0)                                          0.00010
  24            10.0       low     no                                         no         3.7 (s.d. = 1.5)                                          0.01610
  25            13.0       low     no                                         no         3.7 (s.d. = 1.2)                                          0.00320
  26            3.0        high    no                                         no         6.7 (s.d. = 0.6)                                          0.00050
  27            11.0       high    no                                         no         13.0 (s.d. = 3.0)                                         0.00640
  28            ---        high    no                                         yes        8.0 (s.d. = 1.0)                                          0.00

--- information not available (the tumor resection was performed at another institution); PI, positivity values \*, in each case, at least 30 fields were analyzed, and the mean value of the sum of the mitotic figures in 10 high-power fields is shown in the table.

###### 

Immunohistochemical data of neurofibromas and malignant peripheral nerve sheath tumors.

  Group                                               \% of positive cases (n)   Mean PI    Standard deviation   Median PI   PI min/max       IQ range
  --------------------------------------------------- -------------------------- ---------- -------------------- ----------- ---------------- ----------
  **Neurofibromas**                                   2.6% (n = 1)               0.0005     ---                  ---         0.0000/0.0005    ---
      Plexiform neurofibromas                         6.3% (n = 1)               0.0005     ---                  ---         0.0000/0.0005    ---
      Neurofibromas (from NF1 and non-NF1 patients)   0.0% (n = 0)               ---        ---                  ---         ---              ---
  **MPNSTs**                                          64.3% (n = 18)             0.001931   0.0042199            0.000350    0.0000/0.01597   0.0017

PI, positivity index; IQ, interquartile; MPNSTs, malignant peripheral nerve sheath tumors.

###### 

Results of the influence of the clinicopathological variables on the overall and disease-free survival in patients with malignant peripheral nerve sheath tumors.

  Variables                                Total SV(months)   Total SV(p log-rank)   Disease-free SV (months)   Disease-free SV (p log-rank)
  ---------------------------------------- ------------------ ---------------------- -------------------------- ------------------------------
  **Gender**                                                                                                    
      Female                               54.3               0.109                  47.3                       0.118
      Male                                 23.5                                      19.3                       
  **NF1**                                                                                                       
      Yes                                  31.6               **[0.044]{.ul}**       31.4                       0.959
      No                                   59.9                                      41.6                       
  **Location**                                                                                                  
      Trunk (yes/no)                       49.4/42.2          0.955                  47.3/27.4                  0.390
      Limbs (yes/no)                       37.9/47.0          0.937                  25.0/50.5                  0.199
      Lower limb (yes/no)                  37.7/46.4          0.980                  21.9/50.8                  0.108
      Upper limb (yes/no)                  12.2/46.1          0.912                  11.4/40.15                 0.679
      Head and neck (yes/no)               49.0/48.9          0.977                  0.2/39.7                   0.531
  **Treatment performed**                                                                                       
      Surgical resection + radiotherapy    35.9                                      35.886                     0.282
      Other type of treatment              60.0               0.184                  55.629                     
  **Size of the tumor**                                                                                         
      ≤5 cm                                44.7                                      28.9                       0.610
      \>5 cm                               57.6               0.716                  55.4                       
  **Free surgical margins**                                                                                     
     Yes                                   49.7               0.925                  48.57                      0.516
       No                                  55.1                                      41.5                       
  **Local Recurrence**                                                                                          
      Yes                                  46.0               0.606                  ---                        ---
      No                                   60.6                                                                 
  **Metastases**                                                                                                
      Yes                                  54.4               0.135                  ---                        ---
      No                                   23.4                                                                 
  **Histological Grade**                                                                                        
      High                                 31.7               **[0.045]{.ul}**       23.94                      0.095
      Low                                  68.6                                      65.28                      
  **Mitotic index**                                                                                             
      ≥ 10 mitoses/10 high-power fields    24.0               0.051                  21.54                      0.386
      \< 10 mitoses/10 high-power fields   53.7                                      44.77                      
  **Necrosis**                                                                                                  
      Yes                                  19.1               **[0.003]{.ul}**       23.95                      0.138
      No                                   62.4                                      50.23                      
  **Epithelioid Variant**                                                                                       
      Yes                                  \*                 \*                     6.21                       **[0.036]{.ul}**
      No                                   44.49                                     43.98                      
  **Malignant Triton Tumor**                                                                                    
      Yes                                  9.2                0.566                  18.42                      0.958
      No                                   46.3                                      42.26                      
  **Chondrosarcoma differentiation**                                                                            
      Yes                                  54.5               0.511                  46.17                      
      No                                   43.8                                      37.89                      0.356
  **P53 protein expression**                                                                                    
      Positive                             43.8               0.942                  49,1                       0.418
      Negative                             50.9               429                    42.6                       0.502
      Low PI                               38.9                                      46.9                       
      High PI                              43.5                                      49.4                       

SV, survival; PI, positive index; \*, the value could not be calculated because all cases were censored.

###### 

Results of the Cox regression model for significant variables in the univariate analysis of overall survival.

  Steps   Co-variables                                             *p*-value              Exp (B)                95% CI for Exp (B)     
  ------- -------------------------------------------------------- ---------------------- ---------------------- ---------------------- ----------------------
  1       Presence of NF1Histological GradeNecrosisMitotic Index   0.4970.8460.2760.370   0.6271.2330.4261.076   0.1630.1610.0920.917   2.4139.2831.9751.262
  2       Presence of NF1NecrosisMitotic Index                     0.4650.2550.289        0.6090.4131.083        0.1610.0900.935        2.3011.8971.254
  3       NecrosisMitotic Index                                    0.1430.226             0.3431.093             0.0820.947             1.4341.261
  4       **Necrosis**                                             **0.007**              0.199                  0.062                  0.639
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